Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


MCL-1 degradation mediated by JNK activation via MEKK1/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189.

Wang W, Wang YQ, Meng T, Yi JM, Huan XJ, Ma LP, Tong LJ, Chen Y, Ding J, Shen JK, Miao ZH.

Mol Cancer Ther. 2014 Jun;13(6):1480-91. doi: 10.1158/1535-7163.MCT-13-0629.


MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.

Azijli K, Yuvaraj S, van Roosmalen I, Flach K, Giovannetti E, Peters GJ, de Jong S, Kruyt FA.

Apoptosis. 2013 Jul;18(7):851-60. doi: 10.1007/s10495-013-0829-3.


The kinase domain of MEKK1 induces apoptosis by dysregulation of MAP kinase pathways.

Boldt S, Weidle UH, Kolch W.

Exp Cell Res. 2003 Feb 1;283(1):80-90.


Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes.

Hammaker DR, Boyle DL, Inoue T, Firestein GS.

Arthritis Res Ther. 2007;9(3):R57.


A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.

Liu Y, Xie M, Song T, Sheng H, Yu X, Zhang Z.

Pigment Cell Melanoma Res. 2015 Mar;28(2):161-70. doi: 10.1111/pcmr.12325.


MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells.

Yang JS, Hour MJ, Huang WW, Lin KL, Kuo SC, Chung JG.

J Pharmacol Exp Ther. 2010 Aug;334(2):477-88. doi: 10.1124/jpet.109.165415.


The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.

Wang B, Ni Z, Dai X, Qin L, Li X, Xu L, Lian J, He F.

Mol Cancer. 2014 Apr 30;13:98. doi: 10.1186/1476-4598-13-98.


Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.

Chen D, Wang W, Qin JJ, Wang MH, Murugesan S, Nadkarni DH, Velu SE, Wang H, Zhang R.

Curr Cancer Drug Targets. 2013 Jul;13(6):651-60.


Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents.

Sánchez-Pérez T, Ortiz-Ferrón G, López-Rivas A.

Cell Death Differ. 2010 May;17(5):883-94. doi: 10.1038/cdd.2009.176.


Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.

Chen YC, Lu PH, Pan SL, Teng CM, Kuo SC, Lin TP, Ho YF, Huang YC, Guh JH.

Biochem Pharmacol. 2007 Jun 30;74(1):10-9.


A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.

Zhang J, Zhou J, Ren X, Diao Y, Li H, Jiang H, Ding K, Pei D.

Invest New Drugs. 2012 Apr;30(2):490-507. doi: 10.1007/s10637-010-9577-1.


BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.

Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY.

Cancer Res. 2004 Jul 1;64(13):4621-8.


Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.

Doi K, Gowda K, Liu Q, Lin JM, Sung SS, Dower C, Claxton D, Loughran TP Jr, Amin S, Wang HG.

Cancer Biol Ther. 2014;15(12):1688-99. doi: 10.4161/15384047.2014.972799.


Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis.

Terrano DT, Upreti M, Chambers TC.

Mol Cell Biol. 2010 Feb;30(3):640-56. doi: 10.1128/MCB.00882-09.


S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.

Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, Wu MJ, Zhang XW, Shen X, Jiang HL, Meng LH, Ding J.

PLoS One. 2009;4(3):e4881. doi: 10.1371/journal.pone.0004881.


Activation mechanism of c-Jun amino-terminal kinase in the course of neural differentiation of P19 embryonic carcinoma cells.

Akiyama S, Yonezawa T, Kudo TA, Li MG, Wang H, Ito M, Yoshioka K, Ninomiya-Tsuji J, Matsumoto K, Kanamaru R, Tamura S, Kobayashi T.

J Biol Chem. 2004 Aug 27;279(35):36616-20.

Items per page

Supplemental Content

Support Center